Earnings ·
United Therapeutics Corporation reported second quarter 2026 financial results for the period ended June 30, 2026
UTHRUNITED THERAPEUTICS Corp
United Therapeutics Corporation reported second quarter 2026 financial results for the period ended June 30, 2026. Total revenues decreased two percent year-over-year to $783.3 million from $798.6 million in the prior year period. Net income increased eight percent to $333.0 million, or $7.27 per diluted share, compared to $309.5 million and $6.41 per diluted share previously. The company announced the submission of new drug applications for ralinepag tablets in pulmonary arterial hypertension and Nebulized Tyvaso in idiopathic fibrosis. Additionally, United Therapeutics disclosed that it repurchased 2,759,343 shares under accelerated share repurchase agreements initiated in March 2026, with $500 million remaining available under the board-approved program.